KIT Mutation Analysis by ddPCR for Mast Cell Disorders

TEST OFFERINGS

The National Comprehensive Cancer Network (NCCN) recommends that *KIT* mutational analysis should be done as first-line testing as opposed to a bone marrow biopsy.

ARUP Laboratories offers one of the first noninvasive tests to use droplet digital polymerase chain reaction (ddPCR) on either peripheral blood or bone marrow to provide accurate, quantitative results for the detection of the *KIT* D816V mutation.

Key Features

- This ultrasensitive assay is easily performed on peripheral blood and can serve as an initial test to ensure that more invasive methods are only performed if necessary.
- The specificity of this assay is 100% and the analytical sensitivity is 0.03%.



Learn more about our KIT D816V test offerings: aruplab.com/KIT-ddPCR